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Abstract
We previously identified metal-responsive transcription factor-1 (MTF-1) as a positive contributor
to mouse fibrosarcoma growth through effects on cell survival, proliferation, tumor angiogenesis
and extracellular matrix remodeling. In the present study, we investigated MTF-1 protein
expression in human tissues by specific immunostaining of both normal and tumor tissue samples.
Immunohistochemical (IHC) staining of a human tissue microarray (TMA), using a unique anti-
human MTF-1 antibody, indicated constitutive MTF-1 expression in most normal tissues, with
liver and testis displaying comparatively high levels of expression. Nevertheless, MTF-1 protein
levels were found to be significantly elevated in diverse human tumor types, including breast, lung
and cervical carcinomas. IHC analysis of a separate panel of full-size tissue sections of human
breast cancers, including tumor and normal adjacent, surrounding tissue, confirmed and extended
the results of the TMA analysis. Taken with our previous findings, this new study suggests a role
for MTF-1 in human tumor development, growth or spread. Moreover, the study suggests that
MTF-1 could be a novel therapeutic target that offers the opportunity to manipulate metal or redox
homeostasis in tumor cells.
Keywords
MTF-1; human tumors; human tissue microarray; immunohistochemistry; human breast
carcinomas
Introduction
Metal-responsive transcription factor-1 (MTF-1) is a unique Cys2His2 zinc finger protein
that is evolutionarily conserved from Drosophila to humans. MTF-1 is activated by heavy
metals, redox stresses, growth factors and cytokines, and its established targets are important
for metal homeostasis, embryogenesis and hematopoiesis.1-3 MTF-1 may also possess
RNA-binding properties that enable it to participate in the post-transcriptional control of
certain stress-related cell survival pathways.4 Pathological consequences of MTF-1 activity
in normal tissue were recently highlighted by reports that MTF-1 has a role in
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neurodegenerative diseases associated with expression of the prion protein receptor.5,6 Our
own studies have revealed roles for MTF-1 in both extracellular matrix (ECM) remodeling
and experimental tumorigenesis.7-11 In this connection, MTF-1 activity is modulated by
metals (e.g., zinc, copper and cadmium), oxidants (e.g., reactive oxygen species, ROS; nitric
oxide, NO), hypoxia, and the cytokine interleukin-6. All of these can contribute to
tumorigenic phenotypes such as enhanced cell survival and proliferation, tumor
angiogenesis, the establishment of tumor microenvironments involving tumor/host cell
inflammatory signaling, and growth factor independence.2,9,10,12-16
The MTF-1 protein contains six highly conserved zinc finger domains (and an N-terminal
cysteine cluster) that regulate its transcriptional activity through direct sensing and binding
of intracellular free zinc (Zn2+) and subsequent DNA binding.2,17 Some activators of
MTF-1 (e.g., ROS, NO, cadmium) exert their effects through release of Zn2+ from cellular
storage proteins such as the metallothionein (MT) family, which is the prototypic MTF-1
target.2,8,12 The underlying mechanisms of action of other MTF-1 inducers, including
hypoxia, are unknown but may involve more complex controls.18 Activated MTF-1 binds to
metal response elements (MREs; TGCRCNC, in which R represents a purine and N is any
nucleotide) within target promoters; the result is either induction or repression of expression,
depending on the target gene, MRE flanking sequences and cellular context.2,18-22
Interactions with other transcription factors—e.g., nuclear factor-κB (NFκB), hypoxia-
inducible transcription factor-1, (HIF-1), nuclear factor 1 and SP1—and posttranslational
modifications (e.g., phosphorylation) of MTF-1 are also likely determinants of its targets
and transactivational activity.2,11,18,23-26
MTF-1 directly induces the expression of several genes that are likely contributors to
phenotypes found in solid tumor microenvironments, such as the genes for MTs (MT1,
MT2A), Zn transporter-1 (ZNT1/SLC30A1) and placenta growth factor (PGF).1,9,18,27
Other MTF-1 targets or partners, such as HIF-1, transforming growth factor-β1 (TGFβ1),
tissue transglutaminase 2 (TGM2), CCAAT/enhancer binding protein α, seleno-protein W,
and N-myc downstream-regulated gene 1,7,10,20,21 are overexpressed (or activated) in
some human tumors, including breast carcinomas; immunostaining patterns of these proteins
are reported to correlate with tumor progression and disease recurrence.8,28-35 MTs, which
are considered to protect cells against ROS and other electrophilic agents, contribute to
proliferation, survival and energy-generating pathways in normal cell types;36-41 it is likely
that they function similarly in tumor cells. Placenta growth factor (PGF) is a member of the
vascular endothelial growth factor (VEGF) family of pro-angiogenic cytokines; PGF
expression correlates with stage, vascularity, survival, metastasis and recurrence of cancers
including breast carcinomas.29,30 HIF-1, which is a critical regulator of the cellular
response to hypoxia, regulates the expression or activity of various proteins involved in
tumorigenesis.42,43 High HIF-1α protein levels occur in several human tumor types and
correlate with increased risk of mortality.34,43 Finally, increased expression of the ECM-
modifying proteins TGFβ1 and TGM correlates with survival and metastasis in some
aggressive tumor types.31-33
Our earlier studies demonstrated the importance of MTF-1 for tumor cell survival and
proliferation, angiogenesis and ECM remodeling, and focused in vivo on mouse tumor
xenografts.7-11 In the present study, for the first time we provide evidence demonstrating
elevated MTF-1 protein expression in human carcinomas, including lung, cervical and breast
carcinomas.
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Specific detection of MTF-1 protein on immunoblots
The MTF-1 antibody was tested for its ability to selectively detect MTF-1 in whole cell
extracts by immunoblotting. Diverse human carcinoma cell lines—MCF-7, MCF-10CA1a,
A549 cells—were selected for this purpose. Figure 1 (left) shows that these cell lines were
found to express similar levels of MTF-1, which migrated at approximately 80–90 kDa. The
specificity of antibody detection was verified by siRNA knockdown of MTF-1 in MCF-7
cultures (right).
MTF-1 visualization in fixed human carcinoma cells
MCF-10CA1a human breast carcinoma cells were used to demonstrate the ability of the
MTF-1 antibody to specifically detect MTF-1 protein in intact cells. MCF-10CA1a cells
were cultured on glass cover slips, fixed and stained with the MTF-1 antibody as described
in Materials and Methods. Negative controls included incubation and staining with pre-
immune serum and peptide blocking of the primary MTF-1 antibody with its immunogen
before the antibody was added to cells. Figure 2A shows that MTF-1 immunostaining was
primarily cytoplasmic in cells, with some weak nuclear and peri-nuclear signals. When the
primary antibody was replaced with pre-immune serum, MTF-1 signals were essentially
undetectable (Fig. 2B). Similar results to those shown in Figure 2B were observed in fixed
cells that were incubated with the immunizing peptide before treatment with the MTF-1
antibody (Fig. 2C). When a random, control peptide was pre-incubated with the primary
MTF-1 antibody, no blocking effect was observed (Fig. 2D). Together, the results in Figures
1 and 2 demonstrate that the MTF-1 antibody is able to recognize human MTF-1 with high
specificity, as indicated by immunoblotting of total cell protein and in fixed cells.
MTF-1 protein expression in human tumor and normal tissues
After validating the MTF-1 antibody, we used it to screen a National Disease Research
Interchange (NDRI) Pan Cancer Tissue Microarray, which represents both tumor and
normal human tissues (see Materials and Methods and Suppl. Table for details), for levels of
MTF-1 protein expression. Figures 3 and 4 show representative immunostaining for MTF-1
protein in normal tissues. MTF-1 protein was detected with various levels of
immunostaining intensity in all normal tissues in the array. This result is consistent with the
ubiquitous expression of this transcription factor in rodent tissues.44 Overall, MTF-1
immunostaining was lowest in brain; moderately high in breast, ovary, pancreas and lung;
and high in thyroid, colon, cervix and kidney. MTF-1 immunostaining was most intense in
liver and testis. The elevated expression levels found in testis are consistent with the results
of an earlier study reporting high mRNA levels of MTF-1 in mouse testis.45 MTF-1
immunostaining was generally cytoplasmic, but showed some nuclear localization,
especially in testis; cytoplasmic MTF-1 immunostaining is consistent with that found in
MCF-10CA1a cells (Fig. 2A). IHC analysis of the array showed relatively high levels of
MTF-1 expression in certain human tumors (e.g., lung, breast and cervical carcinomas)
compared with the corresponding normal tissues (Fig. 4). No significant differences in
MTF-1 staining patterns were found in liver and testicular tumors as compared with normal
tissues (Fig. 4). This observation may reflect the normally high MTF-1 expression patterns
within these two tissue types. As a caveat, the tumor specimens in the array were derived
from needle biopsy samples and thus do not contain normal adjacent, surrounding (called
“surrounding” hereafter) tissue as an internal control; nevertheless, these findings are novel
and indicate that MTF-1 protein expression is high in diverse human carcinomas.
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MTF-1 is highly expressed in human breast tumors
To address the potential caveat mentioned above, we investigated MTF-1 immunostaining in
a panel of full-size, formalin-fixed, paraffin-embedded specimens of human breast
carcinomas that were resected during routine surgical oncology procedures (see Materials
and Methods for details). Figure 5 shows representative examples of MTF-1
immunostaining from this panel: MTF-1 immunostaining intensities varied widely among
individual tumors, but tumor cells within each specimen generally had higher MTF-1
expression than the levels measured in normal tissue. To obtain a semiquantitative estimate
of MTF-1 protein expression levels in the panel of breast carcinoma specimens, two
pathologists (Shi Y and Amin K) independently evaluated MTF-1 immunostaining of the
panel using a scoring system (see Materials and Methods for details). Table 1 shows that
MTF-1 protein expression was significantly higher in tumor than in normal surrounding
tissue for all 71 patient tumors (p value <0.0001).
Discussion
The novel findings described here for MTF-1 protein expression in normal and transformed
human tissues provide important evidence implying a role for MTF-1 in human tumor
development. Our earlier studies showed that MTF-1 contributes to experimental mouse
tumor biology through effects on cell survival, tumor angiogenesis and ECM remodeling.
8-11,13 The present study extends this research to human tumor biology in two ways. First,
we used specific immunostaining of a human tissue microarray with a new antibody to
obtain evidence that MTF-1 expression is elevated in multiple human tumor types, including
breast, lung and cervical carcinomas, compared with its expression in corresponding normal
tissues, (Fig. 4). Second, we used immunostaining of a collection of resected human breast
carcinomas to confirm that MTF-1 protein expression is significantly elevated in a common
human carcinoma relative to expression in normal surrounding tissue (Fig. 5 and Table 1).
It is noteworthy that variable MTF-1 expression was detected by immunostaining in all the
normal human tissues present in the tissue microarray. As mentioned in Results, the
ubiquitous expression of MTF-1 in normal human tissues is consistent with its functional
role in maintaining cellular metal and redox homeostasis.8,21,46 The relatively abundant
levels of MTF-1 protein in human liver and testis tissues (Fig. 4) are consistent with results
of previous studies that found a critical role for MTF-1 in liver development in the mouse,47
as well as high MTF-1 mRNA content in mouse testis.45 The functional importance of
relatively high MTF-1 protein expression and, presumably, activity in these tissues remains
unclear. MTF-1 immunostaining of liver and testicular tumors found no apparent differences
between tumor tissues and the corresponding normal tissues (Fig. 4). This finding may
simply reflect the already high MTF-1 protein expression levels within liver and testis; it is
also consistent with a recent study that showed no significant differences in MTF-1 levels
between human hepatocellular carcinoma samples and matched controls.48
The elevated expression of MTF-1 protein found in breast carcinoma cells in full-size
clinical specimens is consistent with other reports of high expression of a prototypic MTF-1
target, MT2A, within human breast tumors.49,50 Furthermore, MT expression has been
reported to correlate with tumor progression and to predict tamoxifen resistance in invasive
ductal breast cancer.50,51 Other MTF-1 targets and transcriptional partners, such as PGF,
HIF-1α and NFκB, are also overexpressed in breast tumors.29,35,43 In addition, high levels
of Zn2+, an inducer of MTF-1 transactivation and some forms of drug resistance, accumulate
in experimental breast tumors and human breast tumors.52,53 Additional studies are required
to determine any possible correlation between MTF-1 protein levels and histological
classification, proliferation index, tumor stage, prognosis and molecular markers such as
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estrogen and HER2/Neu receptors of human breast tumors. It will also be important to
examine MTF-1 expression in full-size cervical, lung, liver and testicular tumors.
In summary, the findings of the present study, taken with our previous findings,8-11,13
highlight the importance of MTF-1 in human tumors. A recent report showing that a novel
Zn2+ chelator, LOR-253, can inhibit lung and colon xenograft growth, proliferation and
angiogenesis in association with changes in MTF-1 protein levels54 indicates that efforts to
reduce MTF-1 protein expression or MTF-1 activity may represent a therapeutic opportunity
for the treatment of some solid tumors. The underlying mechanisms that regulate MTF-1
expression and transcriptional activation in growing tumors remain unclear, but they may
involve both genetic and microenvironmental components.
Materials and Methods
Production of a MTF-1 antibody for immunohistochemistry
An anti-MTF-1 rabbit polyclonal antibody (NEP-5717; called the “MTF-1 antibody”
hereafter) was custom generated by New England Peptide LLC (Gardner, MA). A sequence
at the N-terminus (but outside the Zn finger domain) of the human MTF-1 protein was
chosen for its potential to generate a specific polyclonal antibody active in both IHC and
immunoblotting analyses. A synthetic peptide, (H2N)-MGEHSPDNNIIYFEAEC-(amide) at
the amino terminus (AA 1–16), was used to immunize rabbits and the resulting serum
antibody was screened by ELISA and affinity purified. The cysteine at the carboxy terminus
of the sequence was added for coupling purposes. Pre-immune serum was also collected and
used as a control in the IHC studies described here. Negative controls included peptide
titration of the antibody.
Cell lines
The MCF-7 human breast carcinoma cell line (maintained in MEM + 1 mM sodium
pyruvate + 10% FBS) and the A549 human non-small cell lung cancer cell line (maintained
in DMEM + 10% FBS) were purchased from the American Type Culture Collection
(ATCC, Manassas, VA). The metastatic human MCF-10CA1a breast carcinoma cell line
was purchased from the Michigan Cancer Foundation and grown in DMEM + 10% FBS.
RNA interference (RNAi) strategy
An siRNA sequence against human MTF-1 was designed from a published mouse sequence.
55 The corresponding human sequence is 3'-CTG ATT CCC ATT GAA GCA CTA-5'. To
determine the specificity of this siRNA against human MTF-1, we used RNAiMAX
(Invitrogen, Carlsbad, CA) to transfect MCF-7 cells with the MTF-1 siRNA or a scrambled
sequence negative control, and subsequently monitored MTF-1 protein and MT-IIA mRNA
levels (by qRT-PCR, probes and primers were from Applied Biosystems, Foster City, CA,
Cat #Hs02379661 g1). Briefly, first-strand cDNA was synthesized from total RNA using
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). PCR condition: 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Reactions were run in triplicates
in a 7300 real-time PCR System (Applied Biosystems, Foster City, CA).
Immunoblotting
Cells were plated in 60 mm culture dishes at 0.7 × 106 cells/dish in DMEM + 10% FBS.
Once the cultures reached about 70% confluency, whole cell extracts were prepared using an
NP-40 based buffered solution (50 mM Tris pH 7.4, 250 mM NaCl, 50 mM NaF, 0.5%
NP-40, 1 mM Na3VO4, 15.7 mM Na4P2O7) containing 2 μg/ml aprotinin, 2 μg/ml leupeptin
and 120 μg/ml PMSF. Final lysate supernatants were prepared by centrifugation at 9,000 xg
at 4°C. Total cell protein was resolved by sodium dodecyl sulfate-polyacrylamide gel
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electrophoresis (SDS-PAGE) using NuPAGE Novex Bis-Tris 4–12% gels and a NuPAGE
MOPS running buffer (Invitrogen). It was then transferred to Immobilon FL membranes
(Millipore Corp., Bedford, MA). Blots were probed with specific antibodies, and proteins
were detected using an Odyssey Infrared Imaging system according to the manufacturer's
protocol (LI-COR, Lincoln, NE). The primary antibody against human MTF-1 is described
above; an antibody for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat #:
sc-25778) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Ponceau S
(Sigma Chemical Co., St. Louis, MO) staining was used to verify equal protein loading and
transfer.
Cellular immunohistochemistry
MCF-10CA1a cells were grown on 18 mm2 glass cover slips to 50% density and processed
for immunofluorescence. Briefly, cells were rinsed with PBS (37°); fixed (20 min) in freshly
prepared 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer; rinsed three times (10 min
each) in PBS; and permeabilized with PBS/0.1% Triton X-100 (30 min) prior to blocking
(30 min) in 10% normal donkey serum in bovine serum albumin (BSA) buffer (2% BSA/0.1
M phosphate buffer, pH 7.4). This medium was aspirated, and the cells were incubated with
the primary MTF-1 antibody (4 μg/ml in BSA buffer) for an additional 30–60 min at room
temperature (RT). To control for primary MTF-1 antibody specificity, this antibody was
preincubated with a x100 molar excess of the 17-mer immunogen (above) or an irrelevant
peptide (NQEQVSP; mw 800.8) for 60 min at RT, centrifuged (50,000 rpm, 4°) to remove
precipitates and incubated with cells as above. Cells were rinsed three times with PBS (10
min each), and then labeled with a Cy3-conjugated donkey anti-rabbit F(ab')2 fragment
antibody [minimally cross-reactive IgG (H + L); Jackson ImmunoResearch, West Grove,
PA] at 5 μg/ml in BSA buffer (30–60 min at room temperature). Cells were next rinsed two
times with PBS (10 min each) followed by a final rinse in 0.1 M Tris, pH 8.5 (5 min). The
cover slips were mounted on microscope slides under an anti-fade medium containing
diamidinophenylindole dihydrochloride (DAPI; ProLong Gold, Molecular Probes/
Invitrogen, Carlsbad, CA) and sealed. Dried salts were removed with de-ionized water, and
the slides were dried and stored at -20°C. Images were obtained using a Leica DM 5500B
microscope (Bannockburn, IL; e.g., at x63 magnification) equipped with a Retiga-SRV
camera (Q-imaging, Surrey, BC) and Image Pro Plus acquisition software (Media
Cybernetics, Bethesda, MD).
IHC of tissue microarray and clinical human breast tumor specimens
The Comprehensive Pan Cancer Tissue Microarray (TMA) was obtained from the NDRI.
This array consists of five separate slides representing 522 tumors (20 tumor types; called
TMA1-4 here) and 120 control biopsies (called TMA5 here) from human tissue. Clinical
breast cancer samples (formalin-fixed, paraffin-embedded human breast cancer specimens)
were obtained from Dr. Murat Ascaroy (Duke University), and handled by standard
oncology procedures.
Tissue sections were deparaffinized with xylene and rehydrated in ethanol solution, and then
endogenous peroxidase activity was quenched by treatment with 3% hydrogen peroxide for
15 min. MTF-1 antigen retrieval was achieved by immersing sections in CytoQ solution
(Innovex Biosciences) followed by microwave irradiation (750 W, two exposures, 4 min/
exposure). After the sections were blocked with 5% donkey serum (15 min), they were
incubated with the primary MTF-1 antibody (1:100 dilution) overnight at 4°C. As a negative
control, some sections were incubated with the non-immune rabbit serum instead of the
primary antibody. All sections were thoroughly rinsed with PBS and incubated with a
biotinylated donkey anti-rabbit secondary antibody (1:2,000 dilution) for about 30 min at
37°C. A streptavidin-peroxidase complex (ABC Kit, Vector Laboratories, Burlingame, CA)
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was added for 30 min at 37°C. Immunostaining was completed by incubation with the
peroxidase substrate diaminobenzidine (DAB) for 5 min. Sections were rinsed and then
counterstained with hematoxylin. Images of whole slides were acquired using an iScan slide
scanner (BioImagene, Inc., Sunnyvale, CA). The resolution of the images was 0.46 μm/pixel
at 20 magnification. Areas of each slide were prescreened, and an area of interest was
manually selected for image processing.
Scoring of the clinical tumor specimens of human breast cancers
Immunostained sections from clinical human breast tumor specimens were evaluated by
using an imaging system consisting of a charge couple device (CCD) camera coupled to a
microscope (Axioskop 2 plus, Carl Zeiss, Berlin, Germany). To estimate the intensity of
immunostaining for MTF-1 in the specimens, images were first inspected at low
magnifications (x25 and x50) and the percentages of positively staining cells in both normal
surrounding tissue and tumor tissue were evaluated (reviewed in ref. 56). Each sample was
next inspected at medium and medium-high magnifications (x100, x200, respectively) to
assign intensity values based on the semi-quantitative scale of 0 to 3, where 0 is no staining,
1 is weak, 2 is moderate and 3 is strong. Immunostaining intensity scores were calculated by
using the following formula: weighted signal intensity = percentage of immunostained cells
× average intensity score.
Statistical analysis
The paired t-test was used to test statistical differences between MTF-1 staining intensities
within tumors and within normal surrounding tissues in 71 human breast cancer specimens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIF-1 hypoxia-inducible transcription factor-1
ZNT1 Zn transporter-1
PGF placenta growth factor
TGFβ1 transforming growth factor-β1
Shi et al. Page 7













TGM2 tissue transglutaminase 2
VEGF vascular endothelial growth factor
NDRI national disease research interchange
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Detecion of MTF-1 protein in cultured human cells. human breast (MCF-10Ca1a, MCF-7)
and lung (a549) carcinoma cells were grown to subconfluence, and whole cell extracts were
used for immunoblotting. To confirm the specificity of the antibody for MTF-1 protein,
MCF-7 cells were transfected with scrambled control or MTF-1 siRNa duplexes 6 d before
harvesting for total protein.
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MTF-1 immunofluorescence detection in a human breast cancer line. MCF-10Ca1a breast
cancer cells were cultured and labeled with (A) affinity -purified MTF-1 antibody, (B) pre-
immune serum, (C) immunogen-blocked MTF-1 antibody, and (D) random, control peptide-
blocked MTF-1 antibody. Each panel is a merged composite of DAPI labeling (pseudo-
colored blue), MTF-1 (red) and DIC (grey) in registration.
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Representative IHC analysis of MTF-1 expression in normal tissue sections from a human.
TMA (x200 magnification). IHC analysis of MTF-1 expression in six normal human tissues.
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Representative IHC analysis of MTF-1 expression in normal and cancer tissue sections from
a human. TMA (x200 magnification). IHC analysis of MTF-1 expression in normal and
tumor tissues of human lung, cervix, breast, liver and testis.
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MTF-1 expression is elevated in human breast cancer tumor tissue compared with normal
surrounding tissue. Clinical human breast tumor specimens (71) were immunostained using
the MTF-1 antibody. (A) Representative image shows both tumor and normal surrounding
tissues in one field taken at x100 magnification. (B and C) Increased magnification (x400)
of tumor (B) and normal tissue (C).
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Table 1
Statistical analysis of protein levels of MTF-1 in human breast cancer patients
Mean (±SEM; N = 71)
Tumor tissue 175.8 (±6.76)
Normal surrounding tissue 123.5 (±5.54)
p-value <0.0001
Immunostained sections from the 71 clinical human breast tumor specimens were evaluated. MTF-1 protein content was semi quantitatively
measured in both the breast tumors and the normal surrounding tissue of each tumor, and a paired t-test was used to test for statistically significant
differences. The data are presented as the mean ± standard error of the mean.
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